Lionel Galicier

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2567337/publications.pdf

Version: 2024-02-01

64 papers	4,009 citations	136950 32 h-index	123424 61 g-index
64 all docs	64 docs citations	64 times ranked	4800 citing authors

#	Article	IF	Citations
1	Characteristics of thrombocytopenia, anasarca, fever, reticulin fibrosis and organomegaly syndrome: a retrospective study from a large Western cohort. British Journal of Haematology, 2022, 196, 599-605.	2.5	5
2	Legâ€type form of idiopathic multicentric Castleman disease associated with severe lower extremity chronic venous/lymphatic disease. EJHaem, 2022, 3, 175-179.	1.0	0
3	Improving the diagnostic efficiency of primary immunodeficiencies with targeted next-generation sequencing. Journal of Allergy and Clinical Immunology, 2021, 147, 734-737.	2.9	17
4	A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP. Blood, 2021, 137, 733-742.	1.4	95
5	Intensive rituximab regimen in immuneâ€mediated thrombotic thrombocytopenic purpura can circumvent unresponsiveness to standard rituximab treatment. British Journal of Haematology, 2021, 192, e21-e25.	2.5	7
6	High dose romiplostim as a rescue therapy for adults with severe bleeding and refractory immune thrombocytopenia. American Journal of Hematology, 2021, 96, E43-E46.	4.1	11
7	Autoimmune hypoglycemia expands the biological spectrum of HHV8+ multicentric Castleman disease. Blood Advances, 2021, 5, 1848-1852.	5.2	2
8	Pure red cell aplasia in systemic lupus erythematosus, a nationwide retrospective cohort and review of the literature. Rheumatology, 2021, 61, 355-366.	1.9	9
9	Characteristics and mid-term follow-up of COVID-19 patients with hematological diseases: a retrospective study from a French tertiary care hospital. Blood Cancer Journal, 2021, 11, 129.	6.2	0
10	Development of thrombotic thrombocytopenic purpura during lenalidomide therapy: three new cases and review of literature. British Journal of Haematology, 2020, 188, 338-340.	2.5	7
11	Clinical characteristics, management and outcome of COVIDâ€19â€associated immune thrombocytopenia: a French multicentre series. British Journal of Haematology, 2020, 190, e224-e229.	2.5	68
12	Rapid identification and characterization of infected cells in blood during chronic active Epstein-Barr virus infection. Journal of Experimental Medicine, 2020, 217, .	8.5	37
13	Management of HIV-infected patients in the intensive care unit. Intensive Care Medicine, 2020, 46, 329-342.	8.2	39
14	A Prospective International Study on Adherence to Treatment in 305 Patients With Flaring <scp>SLE</scp>: Assessment by Drug Levels and Selfâ€Administered Questionnaires. Clinical Pharmacology and Therapeutics, 2019, 106, 374-382.	4.7	30
15	PROMIDISÎ±: AÂT-cell receptor Î± signature associated with immunodeficiencies caused by V(D)J recombination defects. Journal of Allergy and Clinical Immunology, 2019, 143, 325-334.e2.	2.9	43
16	Epidemiology of Castleman disease associated with AA amyloidosis: description of 2 new cases and literature review. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2019, 26, 197-202.	3.0	7
17	Immune thrombotic thrombocytopenic purpura in older patients: prognosis and long-term survival. Blood, 2019, 134, 2209-2217.	1.4	38
18	Bortezomib and dexamethasone, an original approach for treating multiâ€refractory warm autoimmune haemolytic anaemia. British Journal of Haematology, 2019, 187, 124-128.	2.5	29

#	Article	IF	Citations
19	Treatment and outcome of Unicentric Castleman Disease: a retrospective analysis of 71 cases. British Journal of Haematology, 2019, 186, 269-273.	2.5	36
20	CD89 Is a Potent Innate Receptor for Bacteria and Mediates Host Protection from Sepsis. Cell Reports, 2019, 27, 762-775.e5.	6.4	19
21	Autologous¹¹¹Indiumâ€oxinateâ€labelled platelet sequestration study in patients with immune thrombocytopenia treated by thrombopoietin receptorâ€agonists. British Journal of Haematology, 2019, 186, e44-e47.	2.5	8
22	Congenital yellow nail syndrome presenting with eyelid lymphedema and fetal hydrops. JAAD Case Reports, 2019, 5, 1010-1012.	0.8	3
23	Synergistic convergence of microbiota-specific systemic IgG and secretory IgA. Journal of Allergy and Clinical Immunology, 2019, 143, 1575-1585.e4.	2.9	86
24	Intestinal dysbiosis in inflammatory bowel disease associated with primary immunodeficiency. Journal of Allergy and Clinical Immunology, 2019, 143, 775-778.e6.	2.9	28
25	Kaposi sarcomaâ€“associated herpesvirus/human herpesvirus 8â€“associated lymphoproliferative disorders. Blood, 2019, 133, 1186-1190.	1.4	38
26	Microbial ecology perturbation in human IgA deficiency. Science Translational Medicine, 2018, 10, .	12.4	206
27	Identification and characterization of two novel Gammapapillomavirus genomes in skin of an immunosuppressed Epidermodysplasia Verruciformis patient. Virus Research, 2018, 249, 66-68.	2.2	6
28	Note of Republication: A Prospective International Study on Adherence to Treatment in 305 Patients With Flaring SLE: Assessment by Drug Levels and Selfâ€Administered Questionnaires. Clinical Pharmacology and Therapeutics, 2018, 103, 1074-1082.	4.7	48
29	The full spectrum of Castleman disease: 273 patients studied over 20Âyears. British Journal of Haematology, 2018, 180, 206-216.	2.5	137
30	Preemptive rituximab prevents long-term relapses in immune-mediated thrombotic thrombocytopenic purpura. Blood, 2018, 132, 2143-2153.	1.4	102
31	Cutis laxa for diagnosis of Î³1â€heavyâ€chain deposition disease: Report of four cases. Journal of Dermatology, 2018, 45, 1211-1215.	1.2	2
32	A comprehensive analysis of Lymphomaâ€associated haemophagocytic syndrome in a large French multicentre cohort detects some clues to improve prognosis. British Journal of Haematology, 2018, 183, 68-75.	2.5	23
33	The clinical features of cardiac involvement in patients with severe thrombotic thrombocytopenic purpura. Intensive Care Medicine, 2018, 44, 963-965.	8.2	3
34	Autoimmune cytopenias associated with inflammatory bowel diseases: Insights from a multicenter retrospective cohort. Digestive and Liver Disease, 2017, 49, 397-404.	0.9	27
35	Plasma exchange in the intensive care unit: Technical aspects and complications. Journal of Clinical Apheresis, 2017, 32, 405-412.	1.3	44
36	Talc pleurodesis allows long-term remission in HIV-unrelated Human Herpesvirus 8-associated primary effusion lymphoma. Leukemia and Lymphoma, 2017, 58, 1993-1998.	1.3	5

#	Article	IF	Citations
37	Uterine intravascular lymphoma as a cause of fever of unknown origin. Annals of Hematology, 2017, 96, 1891-1896.	1.8	3
38	A randomized and doubleâ€blind controlled trial evaluating the safety and efficacy of rituximab for warm autoâ€immune hemolytic anemia in adults (the RAIHA study). American Journal of Hematology, 2017, 92, 23-27.	4.1	84
39	Classic and extracavitary primary effusion lymphoma in 51 <scp>HIV</scp>â€infected patients from a single institution. American Journal of Hematology, 2016, 91, 233-237.	4.1	89
40	Central nervous system involvement in <scp>AIDS</scp>â€related lymphomas. British Journal of Haematology, 2016, 173, 857-866.	2.5	19
41	Epidemiology and pathophysiology of adulthood-onset thrombotic microangiopathy with severe ADAMTS13 deficiency (thrombotic thrombocytopenic purpura): a cross-sectional analysis of the French national registry for thrombotic microangiopathy. Lancet Haematology,the, 2016, 3, e237-e245.	4.6	218
42	Risk factors associated with intracranial hemorrhage in adults with immune thrombocytopenia: A study of 27 cases. American Journal of Hematology, 2016, 91, E499-E501.	4.1	20
43	Efficacy of a rituximab regimen based on B cell depletion in thrombotic thrombocytopenic purpura with suboptimal response to standard treatment: Results of a phase II, multicenter noncomparative study. American Journal of Hematology, 2016, 91, 1246-1251.	4.1	46
44	Clinical and immunologic phenotype associated with activated phosphoinositide 3-kinase Î´ syndrome 2: AÂcohort study. Journal of Allergy and Clinical Immunology, 2016, 138, 210-218.e9.	2.9	215
45	Hemophagocytic Lymphohistiocytosis Associated WithBartonella henselaeInfection in an HIV-Infected Patient. Clinical Infectious Diseases, 2016, 62, 804-806.	5.8	17
46	Thrombotic Thrombocytopenic Purpura in Black People: Impact of Ethnicity on Survival and Genetic Risk Factors. PLoS ONE, 2016, 11, e0156679.	2.5	38
47	Epsteinâ€“Barr virus viral load in human immunodeficiency virus-positive patients with reactive hemophagocytic syndrome. Infectious Diseases, 2015, 47, 423-427.	2.8	7
48	Emergence of long-lived autoreactive plasma cells in the spleen of primary warm auto-immune hemolytic anemia patients treated with rituximab. Journal of Autoimmunity, 2015, 62, 22-30.	6.5	40
49	Acute Kidney Injury in Adults With Hemophagocytic Lymphohistiocytosis. American Journal of Kidney Diseases, 2015, 65, 851-859.	1.9	77
50	A Web-Based Delphi Study for Eliciting Helpful Criteria in the Positive Diagnosis of Hemophagocytic Syndrome in Adult Patients. PLoS ONE, 2014, 9, e94024.	2.5	65
51	Reactive Hemophagocytic Syndrome in Adults: A Retrospective Analysis of 162 Patients. American Journal of Medicine, 2014, 127, 1118-1125.	1.5	261
52	Characterization of Crohn disease in X-linked inhibitor of apoptosisâ€“deficient male patients and female symptomatic carriers. Journal of Allergy and Clinical Immunology, 2014, 134, 1131-1141.e9.	2.9	101
53	Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura. Blood, 2014, 124, 204-210.	1.4	154
54	Human herpesvirus 8+ polyclonal <scp>I</scp>g<scp>M</scp>Î» <scp>B</scp>â€cell lymphocytosis mimicking plasmablastic leukemia/lymphoma in <scp>HIV</scp>â€infected patients. European Journal of Haematology, 2013, 91, 497-503.	2.2	18

#	Article	IF	Citations
55	B cell depletion in immune thrombocytopenia reveals splenic long-lived plasma cells. Journal of Clinical Investigation, 2013, 123, 432-442.	8.2	154
56	Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center. Critical Care Medicine, 2012, 40, 104-111.	0.9	260
57	Development and validation of a predictive model for death in acquired severe ADAMTS13 deficiency-associated idiopathic thrombotic thrombocytopenic purpura: the French TMA Reference Center experience. Haematologica, 2012, 97, 1181-1186.	3.5	118
58	Rituximab decreases the risk of lymphoma in patients with HIV-associated multicentric Castleman disease. Blood, 2012, 119, 2228-2233.	1.4	98
59	HHV-8 Related Castleman Disease in the Absence of HIV Infection. Blood, 2012, 120, 1578-1578.	1.4	0
60	Reactive haemophagocytic syndrome in 58 HIV-1-infected patients: clinical features, underlying diseases and prognosis. Aids, 2010, 24, 1299-1306.	2.2	92
61	Critical care management of patients with hemophagocytic lymphohistiocytosis. Intensive Care Medicine, 2010, 36, 1695-1702.	8.2	173
62	Predictive Features of Severe Acquired ADAMTS13 Deficiency in Idiopathic Thrombotic Microangiopathies: The French TMA Reference Center Experience. PLoS ONE, 2010, 5, e10208.	2.5	286
63	Intensive chemotherapy regimen (LMB86) for St Jude stage IV AIDS-related Burkitt lymphoma/leukemia: a prospective study. Blood, 2007, 110, 2846-2854.	1.4	68
64	HIV-Associated Non-Hodgkin Lymphoma in 114 Patients with Undetectable HIV Viral Load at NHL Diagnosis.. Blood, 2007, 110, 1578-1578.	1.4	23